Skip to main content
NCBI home page
Gut logoLink to Gut
. 1996 Feb;38(2):229–233. doi: 10.1136/gut.38.2.229

A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.

F I Lee 1, D P Jewell 1, V Mani 1, M R Keighley 1, R D Kingston 1, C O Record 1, R H Grace 1, S Daniels 1, J Patterson 1, K Smith 1
PMCID: PMC1383028  PMID: 8801202

Abstract

Distal ulcerative colitis can be treated with oral or rectal mesalazine, or both. A foam enema preparation has been developed and its efficacy investigated. The aim of this study was to evaluate the efficacy and safety of mesalazine foam enemas compared with prednisolone foam enemas in the treatment of patients with acute distal ulcerative colitis. Patients aged over 18 years presenting with a relapse of distal ulcerative colitis were randomly allocated treatment with mesalazine foam enema (n = 149 evaluable patients) and prednisolone foam enema (n = 146 evaluable patients) for four weeks. A randomised multicentre investigator blind parallel group trial was conducted. It was found that after four weeks of treatment, clinical remission was achieved by 52% of mesalazine treated patients and 31% of patients treated with prednisolone (p < 0.001). There was a trend in favour of more patients in the mesalazine group achieving sigmoidoscopic remission (40% v 31%, p = 0.10). Histological remission was achieved by 27% and 21% of patients receiving mesalazine and prednisolone respectively. Symptoms improved in both treatment groups. Significantly more mesalazine patients had no blood in their stools after four weeks of treatment (67% v 40%, p < 0.001). Prednisolone treated patients had significantly fewer days with liquid stools than mesalazine patients, with a median of 0 and 1 days respectively by week 4 (p = 0.001). In this study mesalazine foam enema was superior to prednisolone foam enema with regards to clinical remission, this was supported by favourable trends in sigmoidoscopic and histological remission rates. Both treatments were well tolerated.

Full text

PDF
229

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Campieri M., Corbelli C., Gionchetti P., Brignola C., Belluzzi A., Di Febo G., Zagni P., Brunetti G., Miglioli M., Barbara L. Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci. 1992 Dec;37(12):1890–1897. doi: 10.1007/BF01308084. [DOI] [PubMed] [Google Scholar]
  2. Campieri M., Lanfranchi G. A., Boschi S., Brignola C., Bazzocchi G., Gionchetti P., Minguzzi M. R., Belluzzi A., Labò G. Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut. 1985 Apr;26(4):400–405. doi: 10.1136/gut.26.4.400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Campieri M., Paoluzi P., D'Albasio G., Brunetti G., Pera A., Barbara L. Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema. Dig Dis Sci. 1993 Oct;38(10):1843–1850. doi: 10.1007/BF01296108. [DOI] [PubMed] [Google Scholar]
  4. Dew M. J., Hughes P., Harries A. D., Williams G., Evans B. K., Rhodes J. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1982 Oct 9;285(6347):1012–1012. doi: 10.1136/bmj.285.6347.1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Greenfield S. M., Punchard N. A., Teare J. P., Thompson R. P. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993 Aug;7(4):369–383. doi: 10.1111/j.1365-2036.1993.tb00110.x. [DOI] [PubMed] [Google Scholar]
  6. McIntyre P. B., Macrae F. A., Berghouse L., English J., Lennard-Jones J. E. Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Gut. 1985 Aug;26(8):822–824. doi: 10.1136/gut.26.8.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. O'Donnell L. J., Arvind A. S., Hoang P., Cameron D., Talbot I. C., Jewell D. P., Lennard-Jones J. E., Farthing M. J. Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. Gut. 1992 Jul;33(7):947–949. doi: 10.1136/gut.33.7.947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut. 1988 May;29(5):669–674. doi: 10.1136/gut.29.5.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Riley S. A., Mani V., Goodman M. J., Herd M. E., Dutt S., Turnberg L. A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988 Jun;94(6):1383–1389. doi: 10.1016/0016-5085(88)90677-4. [DOI] [PubMed] [Google Scholar]
  10. Ruddell W. S., Dickinson R. J., Dixon M. F., Axon A. T. Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam. Gut. 1980 Oct;21(10):885–889. doi: 10.1136/gut.21.10.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sutherland L. R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., Martin T., Sparr J., Prokipchuk E., Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987 Jun;92(6):1894–1898. doi: 10.1016/0016-5085(87)90621-4. [DOI] [PubMed] [Google Scholar]
  12. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Danish 5-ASA Group. Dig Dis Sci. 1987 Jun;32(6):598–602. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES